Amphastar Pharmaceuticals, Inc. (AMPH)
After hours:
| Previous close | 42.14 |
| Open | 42.48 |
| Bid | 42.42 x 200 |
| Ask | 42.50 x 200 |
| Day's range | 41.89 - 43.16 |
| 52-week range | 36.56 - 67.66 |
| Volume | |
| Avg. volume | 368,585 |
| Market cap | 2.077B |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | 14.60 |
| EPS (TTM) | 2.91 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 63.25 |
ZacksWhy Amphastar (AMPH) is Poised to Beat Earnings Estimates Again
Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks3 Generic Drug Stocks to Watch Amid Improving Market Prospects
With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY, and TEVA.
- GuruFocus.com
Insider Sale: CFO, EVP & Treasurer William Peters Sells Shares of Amphastar Pharmaceuticals ...
The transaction was documented in a recent SEC Filing. Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) is a biopharmaceutical company that focuses on the development, manufacturing, and marketing of generic and proprietary injectable, inhalation, and intranasal products. Over the past year, William Peters has sold a total of 141,725 shares and has not made any purchases of the company's stock.
